ABT-126 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cognitive Deficits in Schizophrenia
Conditions
Cognitive Deficits in Schizophrenia
Trial Timeline
Mar 1, 2010 → Sep 1, 2011
NCT ID
NCT01095562About ABT-126 + Placebo
ABT-126 + Placebo is a phase 2 stage product being developed by AbbVie for Cognitive Deficits in Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01095562. Target conditions include Cognitive Deficits in Schizophrenia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01095562 | Phase 2 | Completed |
Competing Products
20 competing products in Cognitive Deficits in Schizophrenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aricept (donepezil hydrochloride) + placebo | Eisai | Approved | 85 |
| Donepezil | Eisai | Approved | 85 |
| Aricept | Eisai | Phase 2 | 52 |
| Donanemab + Aducanumab | Eli Lilly | Phase 3 | 77 |
| SDI-118 + Placebo | AbbVie | Phase 1 | 33 |
| ABT-288 Low Dose + Placebo + ABT-288 High Dose | AbbVie | Phase 2 | 52 |
| AZD5213 + AZD5213 + AZD5213 | AstraZeneca | Phase 2 | 52 |
| MK-8931 | Merck | Phase 1 | 33 |
| Nicotine patch + MK-4334 + Placebo patch + Placebo capsule | Merck | Phase 1 | 33 |
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Exelon (rivastigmine) + Placebo | Novartis | Approved | 85 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Eviplera | Gilead Sciences | Approved | 84 |
| atorvastatin | Pfizer | Pre-clinical | 22 |
| bosutinib | Pfizer | Phase 1 | 32 |
| Aducanumab + Placebo | Biogen | Phase 2 | 49 |
| BIIB080 + BIIB080-matching placebo | Biogen | Phase 2 | 49 |
| BIIB104 | Biogen | Phase 2 | 49 |